Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for Severe COVID-19 in Egypt
NCT04816942Phase 3
Key facts
- Status
- Completed
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Countries
- 1
- Sponsor
- Ministry of Health and Population
- Modality
- Biologic
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 3, open-label, single-arm trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by Ministry of Health and Population. Primary endpoints: COVID-19 Cure rate at 30 days, Degree of clinical improvement at 7 days and 1 more. Started Apr 2020; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Convalescent Plasma
Patients receiving two units of ABO compatible COVID-19 convalescent plasma.
03
Who it enrols
Patients with laboratory-confirmed COVID-19 and severe or life-threatening disease, including respiratory distress or organ failure.
04
Endpoints
Primary
COVID-19 Cure rate
Degree of clinical improvement
Case Fatality Rate
Beyond the preview
Go deeper on NCT04816942.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816942.